Amgen vs. Novo Nordisk: Which Healthcare Giant's Stock Is a Better Buy in 2026?

Impact · against what's priced in

The article provides no new catalysts for Amgen, McKesson, Cencora, or Cardinal Health, as its financial data merely confirms the revenue growth and customer concentration risks already baked into their valuations. Novo Nordisk's scale remains a positive fundamental, but the provided text offers no new developments to shift its current price trajectory.

MCK+0.00

Doesn't touch the price's assumptions

In context

The mention of McKesson as one of Amgen's primary distributors does not alter the growth or margin assumptions driving McKesson's own stock price.